Results 131 to 140 of about 51,886 (205)

LDLRAD4 is a potential diagnostic and prognostic biomarker correlated with immune infiltration in myelodysplastic syndromes. [PDF]

Front Genet
Xu M, Wu S, Zhang K, Nie L, Li Q, Zhong J, Zhang Y, He H.   +7 more
europepmc   +1 more source

Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes. [PDF]

Blood Res
Hong J.
europepmc   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. [PDF]

Am J Hematol
Komrokji RS, Hayati S, Ugidos M, Garcia-Manero G, Della Porta MG, Zeidan AM, Santini V, Platzbecker U, Gandhi AK, Suragani RNVS.   +9 more
europepmc   +1 more source

A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice. [PDF]

Pract Lab Med
Wang X, Huang J, Xi J, Liu H, Yuan Y.
europepmc   +1 more source

Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series. [PDF]

Haematologica
Izraeli S.
europepmc   +1 more source

Prognosis of the transformation of myelodysplastic syndromes to acute myeloid leukemia: A retrospective study. [PDF]

Medicine (Baltimore)
Wang Y, Hu F, Ke J.
europepmc   +1 more source

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study. [PDF]

Cancers (Basel)
Lai B, Mei C, Yan X, Chen L, Wang Y, Sheng L, Tang S, Mao L, Zhang P, Sun Y, Xie W, Zhou, Mai W, Wang H, Ma L, Lou Y, Wu W, Jiang H, Zhang J, Ye B, Tong H, Ouyang G.   +21 more
europepmc   +1 more source

Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes. [PDF]

Blood Adv
Sarchi M, Clough CA, Gallì A, Picone C, Ferrari B, Crosse EI, Baquero Galvis LD, Fiducioso C, Aydinyan N, Creamer JP, Pozzi S, Molteni E, Elena C, Bradley RK, Malcovati L, Doulatov S.   +15 more
europepmc   +1 more source

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial. [PDF]

Br J Haematol
Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Díez-Campelo M, de Paz R, Santillana GS, Thépot S, Kaźmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM.   +20 more
europepmc   +1 more source

Base editing platform to investigate pathogenic SAMD9 mutations in paediatric myelodysplastic syndromes. [PDF]

Br J Haematol
Canciani G, Lecis M, Frati G, D'Agostino V, Gelosi M, Del Bufalo F, Palumbo G, Palma P, Locatelli F, Ceglie G.   +9 more
europepmc   +1 more source